```html

Yohimbe (Pausinystalia johimbe) Toxicity – A Comprehensive Medical Guide

Overview

Yohimbe is a tree native to Central and Western Africa whose bark contains the alkaloid yohimbine. In dietary‑supplement form, yohimbe bark extract is marketed for erectile dysfunction, weight loss, and “energy boosting.” Because the supplement is not regulated by the U.S. Food & Drug Administration (FDA), the amount of yohimbine can vary dramatically, and contamination with other stimulants is common.

Who it affects: Toxicity can occur in anyone who ingests yohimbe, but certain groups are more vulnerable:

• Adults using it for sexual performance or weight loss.
• Individuals taking prescription stimulants, antidepressants, or antihypertensives that interact with yohimbine.
• People with pre‑existing heart disease, high blood pressure, liver or kidney disease, or anxiety disorders.

Prevalence: Exact incidence is difficult to track because cases are often reported as “herbal supplement poisoning.” The American Association of Poison Control Centers (AAPCC) recorded ~2,500 yohimbe‑related exposure calls in the United States in 2022, a 13 % increase from 2020, with 12 % of those requiring hospitalization.

Symptoms

Yohimbe toxicity presents with a spectrum of autonomic, cardiovascular, neurological, and psychiatric findings. Symptoms can appear within 30 minutes of ingestion and may persist for several hours due to yohimbine’s half‑life of ~0.5–2 hours, although metabolites can linger.

Cardiovascular

• Rapid heart rate (tachycardia) – beats >100 bpm, often irregular.
• Elevated blood pressure (hypertension) – systolic >140 mmHg or diastolic >90 mmHg.
• Palpitations – sensation of pounding or fluttering.
• Chest pain – may mimic angina, especially in coronary artery disease.
• Arrhythmias – atrial fibrillation, ventricular premature beats.

Neurologic & Psychiatric

• Anxiety, agitation, or panic attacks – often accompanied by restlessness.
• Insomnia – difficulty falling or staying asleep.
• Tremor or muscle twitching.
• Seizures – rare but reported with high doses.
• Headache – throbbing or tension‑type.
• Confusion or delirium – especially in older adults.

Gastrointestinal

• Nausea & vomiting
• Abdominal cramping
• Diarrhea

Other

• Hyperthermia (body temperature >38 °C/100.4 °F)
• Excessive sweating (diaphoresis)
• Dry mouth
• Urinary retention

Causes and Risk Factors

Primary cause

Ingestion of yohimbe bark extract containing high concentrations of yohimbine (often >10 mg per dose) – either as a stand‑alone supplement, a “herbal blend,” or a contaminated product.

Risk amplifiers

• Concurrent medications: β‑blockers, antihypertensives, MAO inhibitors, SSRIs, trazodone, and other serotonergic agents can potentiate toxicity.
• Underlying medical conditions: Cardiovascular disease, uncontrolled hypertension, hyperthyroidism, liver impairment (reduced metabolism), chronic kidney disease, anxiety or panic disorders.
• High‑dose or “stacked” use: Users often combine yohimbe with caffeine, ephedra, or synephrine for synergistic “energy” effects, greatly increasing sympathetic stimulation.
• Age: Elderly patients have reduced hepatic clearance and are more prone to arrhythmias.
• Pregnancy & lactation: Limited data suggest increased risk of uterine hyperstimulation; thus, it’s contraindicated.

Diagnosis

There is no single laboratory test for yohimbe toxicity. Diagnosis relies on a combination of clinical suspicion, exposure history, and exclusion of other causes.

History & Physical Examination

• Ask specifically about herbal supplement use, dose, timing, and other substances taken.
• Document vital signs, cardiac rhythm, neurologic status, and signs of dehydration.

Laboratory Tests

• Serum electrolytes & renal function – to detect dehydration or kidney injury.
• Liver enzymes (AST, ALT, ALP, bilirubin) – assess hepatic metabolism.
• Complete blood count (CBC) – rule out infection or hemolysis.
• Plasma yohimbine level – not routinely available; can be measured by specialized toxicology labs using LC‑MS/MS.
• Drug screen – urine immunoassay to detect co‑ingested stimulants.

Cardiac Monitoring

• 12‑lead ECG on presentation – look for tachycardia, QTc prolongation, or arrhythmias.
• Continuous telemetry for patients with hemodynamic instability.

Imaging (if indicated)

• Chest X‑ray – assess for pulmonary edema in severe hypertension.
• Head CT – if seizures or altered mental status are present.

Treatment Options

Management is principally supportive and aims to counteract excessive sympathetic activity.

Immediate Measures

• Stop exposure – discontinue all yohimbe‑containing products.
• Airway, Breathing, Circulation (ABCs) – provide supplemental oxygen, secure airway if consciousness is impaired.
• IV Access – large‑bore catheter for fluid resuscitation and medication administration.

Pharmacologic Interventions

• Beta‑blockers (e.g., propranolol, esmolol) – blunt tachycardia and hypertension; use cautiously in asthmatic patients.
• Alpha‑adrenergic antagonists (e.g., phentolamine) – effective for severe hypertension refractory to beta‑blockade.
• Benzodiazepines (e.g., lorazepam, diazepam) – treat agitation, anxiety, or seizures.
• Anti‑arrhythmic agents – amiodarone or procainamide if life‑threatening arrhythmias develop.
• Activated charcoal – if presentation is within 1–2 hours of ingestion and airway is protected.

Supportive Care

• IV isotonic fluids (e.g., normal saline) to correct dehydration and hypotension.
• Cooling measures for hyperthermia (cool blankets, acetaminophen).
• Monitoring electrolytes; replace potassium or magnesium as needed to prevent arrhythmias.

Disposition

• Mild cases (isolated tachycardia, normal BP) may be observed in the ED for 4–6 hours and discharged with counseling.
• Moderate‑to‑severe cases (persistent hypertension, arrhythmias, seizures) require admission to a monitored unit.

Living with Yohimbe (Pausinystalia johimbe) Toxicity

If you have experienced yohimbe toxicity, ongoing management focuses on preventing recurrence and addressing any organ injury.

Medical Follow‑up

• Cardiology clinic visit 1–2 weeks after discharge to repeat ECG and blood pressure check.
• Renal and liver function tests at 1 month to verify recovery.
• Psychiatric evaluation if anxiety or panic symptoms persist.

Lifestyle Strategies

• Read labels: Avoid any product that lists “yohimbe,” “yohimbine,” “Pausinystalia johimbe,” or “African tree bark”.
• Maintain a medication list and share it with every health‑care provider.
• Adopt stress‑reduction techniques (mindfulness, yoga, moderate exercise) that do not rely on stimulants.
• Stay hydrated and limit caffeine to ≤200 mg/day, as caffeine adds sympathetic load.
• Consider a certified supplement verification program (e.g., USP Verified, NSF) when choosing any herbal product.

Monitoring at Home

• Check blood pressure daily for 2 weeks after the event.
• Record heart rate and any palpitations in a symptom diary.
• Seek medical review if you notice recurrent tachycardia, dizziness, or new chest pain.

Prevention

• Regulatory awareness: Understand that the FDA does not approve yohimbe for any indication; it is sold as a “dietary supplement.”
• Educate yourself about the potential side‑effects before trying any “natural” performance enhancer.
• Consult a health professional before combining supplements with prescription drugs.
• Purchase from reputable manufacturers that provide third‑party testing results.
• Avoid “stacking” yohimbe with other stimulants (caffeine, ephedra, synephrine, DMAA).
• Pregnant or nursing individuals should completely avoid yohimbe‑containing products.

Complications

If not promptly treated, yohimbe toxicity can lead to serious, potentially irreversible sequelae:

• Cardiac complications: Myocardial infarction, heart failure, sustained ventricular tachycardia, or sudden cardiac death.
• Stroke secondary to severe hypertension or arrhythmia‑induced emboli.
• Seizure‑related injury – falls, head trauma.
• Acute kidney injury from rhabdomyolysis or prolonged hypotension.
• Psychiatric sequelae – persistent anxiety, insomnia, or substance‑use disorder.

Long‑term data are limited, but case series indicate that patients with pre‑existing cardiovascular disease have a 2‑ to 3‑fold higher risk of fatal outcomes after severe yohimbe exposure.<sup>1</sup>

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Yohimbe (herbal supplement).” 2024; CDC. “Drug Overdose Data.” 2023; NIH Toxicology Data Network. “Yohimbine.” 2022; WHO. “Safety of Herbal Medicines.” 2023; Cleveland Clinic. “Herbal Supplement Toxicity.” 2024; JAMA Netw Open. “Emergency Department Visits for Dietary Supplement Exposures, 2022.”

```